>
Fredun Pharmaceuticals logo

539730 - Fredun Pharmaceuticals Share Price

₹434.6 -22.0  -4.9%

Last Trade - 20/04/21

Sector
Healthcare
Size
Micro Cap
Market Cap £16.6m
Enterprise Value £18.1m
Revenue £11.4m
Position in Universe 1468th / 3108
Bullish
Bearish
Unlock 539730 Revenue
Momentum
Relative Strength (%)
1m -1.90%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -27.2%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Mar 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
253.6 423.2 567 580.7 963.2 1,128 +34.8%
+11.5 +309.8 +29.0 +22.7 +55.7 -58.9
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the nine months ended 31 December 2020, FredunPharmaceuticals Ltd revenues increased 8% to RS929.1M. Netincome increased 3% to RS22M. Revenues reflect Net Sales/IncomeFrom Operation (Net of increase of 5% to RS904.3M.Net income was partially offset by Exceptional items /Prior Period Item increase from RS0K to RS11.6M (expense),Employess benefits expenses increase of 12% to RS61.9M(expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

539730 Revenue Unlock 539730 Revenue

Net Income

539730 Net Income Unlock 539730 Revenue

Normalised EPS

539730 Normalised EPS Unlock 539730 Revenue

PE Ratio Range

539730 PE Ratio Range Unlock 539730 Revenue

Dividend Yield Range

539730 Dividend Yield Range Unlock 539730 Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
539730 EPS Forecasts Unlock 539730 Revenue
Profile Summary

Fredun Pharmaceuticals Ltd. is an India-based pharmaceutical company. The Company is engaged in the manufacturing and sale of pharmaceutical formulations. The Company’s products include I V fluids, disposable syringes, infusion sets, surgical gloves and cottons, iron supplements, diuretic, anti-obesity and anti-diabetic products. The Company primarily exports its products to Africa, Southeast Asia, and Commonwealth of Independent States (CIS) countries.

Directors
Last Annual March 31st, 2020
Last Interim December 31st, 2020
Incorporated June 8, 1987
Public Since March 17, 2016
No. of Shareholders: 1,478
No. of Employees: n/a
Sector Healthcare
Industry Pharmaceuticals
Index
Exchange Bombay Stock Exchange
Shares in Issue 3,989,634
Free Float (0.0%)
Eligible for
ISAs
SIPPs
539730 Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for 539730
Upcoming Events for 539730
Tuesday 28th September, 2021 Estimate
Fredun Pharmaceuticals Ltd Annual Shareholders Meeting
Frequently Asked Questions for Fredun Pharmaceuticals
What is the Fredun Pharmaceuticals share price?

As of 20/04/21, shares in Fredun Pharmaceuticals are trading at ₹434.6, giving the company a market capitalisation of £16.6m. This share price information is delayed by 15 minutes.

How has the Fredun Pharmaceuticals share price performed this year?

Shares in Fredun Pharmaceuticals are currently trading at ₹434.6 and the price has moved by 0.131k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Fredun Pharmaceuticals price has moved by 49.4% over the past year.

What are the analyst and broker recommendations for Fredun Pharmaceuticals?

There are no analysts currently covering Fredun Pharmaceuticals.

When will Fredun Pharmaceuticals next release its financial results?

Fredun Pharmaceuticals is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Fredun Pharmaceuticals dividend yield?

The Fredun Pharmaceuticals dividend yield is 0.15% based on the trailing twelve month period.

Does Fredun Pharmaceuticals pay a dividend?

Last year, Fredun Pharmaceuticals paid a total dividend of 0.66, and it currently has a trailing dividend yield of 0.15%. Looking ahead, Fredun Pharmaceuticals has not announced an ex-dividend date yet.

When does Fredun Pharmaceuticals next pay dividends?

Fredun Pharmaceuticals has yet to annouce their ex-dividend date. The historic dividend yield on Fredun Pharmaceuticals shares is currently 0.15%.

How do I buy Fredun Pharmaceuticals shares?

To buy shares in Fredun Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Fredun Pharmaceuticals?

Shares in Fredun Pharmaceuticals are currently trading at ₹434.6, giving the company a market capitalisation of £16.6m.

Where are Fredun Pharmaceuticals shares listed? Where are Fredun Pharmaceuticals shares listed?

Here are the trading details for Fredun Pharmaceuticals:

Country of listing: India
Exchange: BSE
Ticker Symbol: 539730
What kind of share is Fredun Pharmaceuticals?

Based on an overall assessment of its quality, value and momentum, Fredun Pharmaceuticals is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Fredun Pharmaceuticals share price forecast 2021?

We were not able to load any forecast data for Fredun Pharmaceuticals.

How can I tell whether the Fredun Pharmaceuticals share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Fredun Pharmaceuticals. Over the past six months, the relative strength of its shares against the market has been 39.78%. At the current price of ₹434.6, shares in Fredun Pharmaceuticals are trading at 30.28% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Fredun Pharmaceuticals PE Ratio?

The Fredun Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is 55.32. The shares are currently trading at ₹434.6.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Fredun Pharmaceuticals?

We were unable to find the directors for Fredun Pharmaceuticals.

Who are the major shareholders of Fredun Pharmaceuticals?

Here are the top five shareholders of Fredun Pharmaceuticals based on the size of their shareholding:

Medhora (Daulat Nariman) Individual Investor
Percentage owned: 33.6% (1.34m shares)
Medhora (Narman) Individual Investor
Percentage owned: 14.42% (575k shares)
Vora (Nikhil) Individual Investor
Percentage owned: 5.85% (233k shares)
Nariman (Fredun Medora) Individual Investor
Percentage owned: 4.01% (160k shares)
Bank of India Ltd Corporation
Percentage owned: 1.88% (75.0k shares)
Similar to 539730
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.